About five months ago Passage Bio that\nbasically produces gene therapies for not so common monogenic CNS disease, in\npartnership with Catalent’s paragon launched a unit that is devoted to manufacturing\nsuite Paragon Harman’s, MD, facility. The other cGMP suite whose worth is not\nbeing revealed yet is expected to hit it’s functional phase from mid-2020 and\nis support Passage Bio’s supply requirements from clinical through commercial\nphases.<\/p>\n\n\n\n
Stephen Squinto, P.hd, co-founder and\nInterim CEO at Passage Bio stated that \u201cPassage\nwill work contractually with Paragon to conduct GMP manufacturing batches of\nour AAV material for clinical development across all 3 programs which are on\ntrack for clinical development in 2020. Beyond that, we expect to utilize our\nnew dedicated suite for all future GMP manufacturing needs,\u201d<\/em><\/p>\n\n\n\n In a statement by Stephen Squinto it’s the\ncollaboration was announced and in the same announcement Squinto added that\nthis collaboration of Passage Bio with Paragon \u201cis a key facet of our business\nplan.\u201d<\/p>\n\n\n\n Moreover, this manufacturing unit is\nexpected to be huge and will be located approximately five miles southwest of\nBaltimore\/Washington International Thurgood Marshall Airport. The suite is also\nwithin the 150,000-square-foot the older warehouse that Paragon modified into a\ncontract advancement facility that opened in April.<\/p>\n\n\n\n The company Passage Bio is in a phase\ncalled IND-enabling phase and that for three of its programs, of which two are expected\nto begin clinical development in the first half of 2020!<\/p>\n","protected":false},"excerpt":{"rendered":" About five months ago Passage Bio that basically produces gene therapies for not so common monogenic CNS disease, in partnership with Catalent’s paragon launched a unit that is devoted to manufacturing suite Paragon Harman’s, MD, facility. The other cGMP suite whose worth is not being revealed yet is expected to hit it’s functional phase from […]<\/p>\n","protected":false},"author":2,"featured_media":328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/327"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=327"}],"version-history":[{"count":1,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/327\/revisions"}],"predecessor-version":[{"id":329,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/327\/revisions\/329"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/328"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}